Listing & Compliance Notices

MARKETWISE, INC. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(c)(4)).

“October 19, 2023, MarketWise, Inc. (the “Company”) notified the Nasdaq Listing Qualifications Department (“Nasdaq”) that, due to the resignation of Mark Gerhard and Riaan Hodgson (as described herein), the Company no longer complies with Nasdaq’s audit committee composition requirements as set forth in Listing Rule 5605. The Company informed Nasdaq that it intends to regain compliance with Listing Rule 5605 within the 180-day cure period provided under Listing Rule 5605(c)(4). To that end, the Board of Directors (the “Board”) of the Company is currently seeking to identify director candidates”

Crown Electrokinetics Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“October 19, 2023, Crown Electrokinetics Corp. (the “Company”) received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until April 16, 2024, to re”

NRX Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“October 17, 2023, NRx Pharmaceuticals, Inc. (the “Company”) received formal notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s non-compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”), the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which”

Arcimoto Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H), 5810(c)(3)(A)(ii)).

“October 20, 2023, Arcimoto, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price of the Company’s common stock, no par value (the “Common Stock”), had closed below $1.00 per share for 30 consecutive business days and, as a result, the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), which sets forth the minimum bid price requirement for continued listing on the Global Market (the “Minimum Bid Requirement“). Nasdaq’s notice has no immediate effect on the listing of the”

FiEE, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(c)(4)).

“October 19, 2023, Minim, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that, because of George I. Kassas’ resignation from the Company’s board and audit committee, effective September 15, 2023, the Company is not in compliance with Nasdaq’s rules for continued listing under Nasdaq Listing Rule 5605. Rule 5605 requires, in part, that listed companies have an audit committee that consists of at least three members. Pursuant to Nasdaq Listing Rule 5605(c)(4), the Company has (i) until the Company’s next annual shareholders’ meeting, or (ii) if the Comp”

ESPORTS ENTERTAINMENT GROUP, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5810(c)(3)(A)(iii), 5550(a)(2)).

“October 20, 2023, Esports Entertainment Group, Inc. (the “Company”) received a deficiency notification letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”) because the bid price for the Company’s common stock had closed at or below $0.10 per share for ten consecutive trading days. The notification letter from Nasdaq advised the Company that the trading of its securities will be suspended at the opening of business on Octobe”

NextPlay Technologies Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“. If the Company fails to file the Regular Reports with the Commission by November 27, 2023, Nasdaq will provide a written notification to the Company that its securities will be delisted. At that time, the Company may appeal the Nasdaq staff’s determination to a Hearings Panel under Nasdaq Listing Rule 5815. Forward Looking Statement. The Company cautions you that statements included in this Current Report on Form 8-K (this “Report”) that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,””

Enlightify Inc. received a nyse noncompliance notice notice regarding late filing (rules 802.01E).

“October 16, 2023, China Green Agriculture, Inc. (the “Company”) received a notice from the New York Stock Exchange (the “NYSE”) indicating that the Company is not in compliance with the NYSE’s continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (the “2023 Form 10-K”). As reported by the Company in its Form 12b-25 filed with the Securities and Exchange Commission (the “SEC”) on October 2, 2023, the Company w”

U S GLOBAL INVESTORS INC received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“October 16, 2023, U.S. Global Investors, Inc. (the “Company”) received a letter (the “Non-Compliance Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the Company has not filed its Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (the “Form 10-K”) within the prescribed time period, the Company is not in compliance with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1). In accordance with Nasdaq Listing Rules, the Company has 60 calendar days to submit a plan to regain c”

MGO Global Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“October 18, 2023, the common stock of the Company had not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until April 16, 2024 (the “Compliance Period”), to regain compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid Price Rule by April 16, 2024, the Company may be eligible for an additional 180-day period to”

FutureTech II Acquisition Corp. received a nasdaq deficiency notice notice regarding other (rules 5450(a)(2)).

“ss A Common Stock remain outstanding. October 16, 2023, the Company received a written notice (the “ Notice ”) from the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, the Company is not in compliance with Nasdaq Listing Rule 5450(a)(2) (the “ Minimum Total Holders Rule ”), which requires the Company to have at least 400 total holders for continued listing on the Nasdaq Global Market. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Com”

FAT PROJECTS ACQUISITION CORP received a nasdaq deficiency notice notice regarding other (rules 5450(b)(2)(B)).

“October 17, 2023, received a written notice (the “ Notice ”) from Nasdaq indicating that the staff of the Nasdaq Listing Qualifications Department (the “ Staff ”) has determined that the Company did not return to compliance with Listing Rule 5450(b)(2)(B) by October 16, 2023, and as a result the Company’s securities will be delisted from the Nasdaq Global Market at the opening of business on October 26, 2023 unless the Company requests an appeal to a Nasdaq hearing panel by October 24, 2024. The Company intends to timely appeal the Staff’s determination to a Nasdaq hearing panel, which will st”

Roth CH Acquisition Co. received a nasdaq deficiency notice notice regarding shareholders (rules 5450(a)(2)).

“October 16, 2023, Roth CH Acquisition Co. (formerly known as TKB Critical Technologies 1) (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company was not in compliance with Listing Rule 5450(a)(2), which requires the Company to have at least 400 shareholders for continued listing on the Nasdaq Global Market (the “Minimum Total Holders Rule”). The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or”

DevvStream Corp. received a nasdaq deficiency notice notice regarding other (rules 5450(a)(2)).

“October 16, 2023, Focus Impact Acquisition Corp., a Delaware corporation (the “Company”), received a written notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was no longer in compliance with Nasdaq Listing Rule 5450(a)(2), which requires a minimum of 400 total holders for continued listing on the Nasdaq Global Market (the “Minimum Public Holders Rule”). The Notice states that the Company has 45 calendar days from the date of the Notice to submit a plan to regain compliance with the Minimum Public Holders”

Fortune Rise Acquisition Corp received a nasdaq noncompliance notice notice regarding market value (rules 5450(b)(2)(A)).

“August 21, 2023, the Company received a written notice (the “Previous Notice”) from the Staff notifying the Company that, for the last 30 consecutive business days, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $50 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “Market Value Standard”). The Staff also noted that the Company does not meet the requirements under Nasdaq Listing Rule 5450(b)(3)(A) (Total Assets/Total Revenue Standard). An indicator will be displayed with quotation information”

Fortune Rise Acquisition Corp received a nasdaq noncompliance notice notice regarding shareholders (rules 5450(a)(2)).

“October 16, 2023, the Company received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, the Company is not in compliance with Nasdaq Listing Rule 5450(a)(2) (the “Minimum Total Holders Rule”), which requires the Company to have at least 400 total holders for continued listing on the Nasdaq Global Market. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Global Market.”

Local Bounti Corporation/DE received a nyse delisting notice notice regarding other (rules 802.01D).

“October 18, 2023, the NYSE provided written notice to the Company and publicly announced that NYSE Regulation has determined to commence proceedings to delist the Warrants and that the Warrants are no longer suitable for listing based on “abnormally low” price levels, pursuant to Section 802.01D of the NYSE Listed Company Manual. To effect the delisting, the NYSE will apply to the Securities and Exchange Commission to delist the Warrants upon completion of applicable procedures. The Company is still evaluating whether it will appeal the NYSE’s determination. Trading in the Company’s common sto”

Fusion Acquisition Corp. II received a nyse delisting notice notice regarding market value (rules 802.01B).

“, listed to trade on the NYSE under the symbol “FSNB.U” (the Units”) and (ii) the Class A Common Stock (together with the Units, the “Company Securities”), listed to trade on the NYSE under the symbol “FSNB.” The notification states that NYSE Regulation reached its determination pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring a listed acquisition company to maintain an average aggregate global market capitalization attributable to its publicly-held shares over a consecutive thirty-trading day p”

Terran Orbital Corp received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“October 20, 2023, Terran Orbital Corporation (the “Company”) received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual (“Section 802.01C”) because the average closing price of the Company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period ended October 18, 2023. The Notice does not result in the immediate delisting of the Company’s common stock from the NYSE. In accordance with applicable NYSE rules, the”

JOANN Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“October 19, 2023 (the “Notice Date”), JOANN Inc. (the “Company”) received a written notice (the “Bid Price Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”), because the closing bid price of the Company’s common stock, par value $0.01 per share (the “Common Stock”), was below $1.00 per share for 30 consecutive business days. The Bid Price Notice provided tha”

Sensei Biotherapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“October 17, 2023, Sensei Biotherapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the minimum bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until April 15, 2024, to regain compliance”

RYTHM, Inc. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“October 17, 2023, the Company received a Staff Delisting Determination (the “Staff Determination”) from the Listing Qualifications Department of Nasdaq notifying the Company that it was not in compliance with Nasdaq’s continued listing requirements under the Listing Rule as a result of its failure to file the Delinquent Reports in a timely manner. The Staff Determination has no immediate effect and will not immediately result in the suspension of trading or delisting of the Company’s shares of common stock. Accordingly, the Company intends to timely request a hearing before the Nasdaq Hearings”

Jasper Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(ii)).

“October 18, 2023, Jasper Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s voting common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A)(ii), the Company has been provided an initial period of 180 calendar days, or until April 15, 2024, to regain compliance.”

AKUMIN INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1), 5550(b)(2), 5550(b)(3)).

“h will remove the Company’s securities from being listed on Nasdaq. 2 The Staff Delisting Determination is based on the Company’s continued non-compliance with (i) the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market (the “Capital Market”) under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) and (ii) Nasdaq Listing Rule 5550(b)(1) (the “Equity Standard”), pursuant to which companies are required to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the Capital Market, or either of the alternatives to compliance with”

AKUMIN INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5550(b)(1)).

“h will remove the Company’s securities from being listed on Nasdaq. 2 The Staff Delisting Determination is based on the Company’s continued non-compliance with (i) the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market (the “Capital Market”) under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) and (ii) Nasdaq Listing Rule 5550(b)(1) (the “Equity Standard”), pursuant to which companies are required to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the Capital Market, or either of the alternatives to compliance with”

Gossamer Bio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“hrough October 18, 2023, the Company’s common stock, $0.0001 par value per share (the “Common Stock”), had not maintained a minimum bid price of $1.00 per share, required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). Nasdaq’s written notice does not result in the immediate delisting of the Common Stock from the Nasdaq Global Market In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has 180 calendar days, or until April 16, 2024 (the “Compliance Date”), to regain compliance with the Minimum Bid Price Requirement.”

Outlook Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“October 16, 2023, Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 32 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accorda”

Tonix Pharmaceuticals Holding Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq listing rules, the Company has been provided a period of 180 calendar days, or until April 15, 2024, in which to regain compliance. In order to regain compliance with the Minimum Bid Price Requirement, the closing bid price”

TALPHERA, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).

“October 18, 2023, AcelRx Pharmaceuticals, Inc. (the “Company”) received written notice (the “Notice”) from the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecu”

RYVYL Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“October 19, 2023, the Company received a determination letter (the “Letter”) from the Staff of Nasdaq stating that the Company is not in compliance with the Market Value of Listed Securities (“MVLS”) Standard, since the Company’s common stock, par value $0.001, was below the $35 million minimum MVLS requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(b)(2) and had not been at least $35 million for the previous 30 consecutive business days. As such, the Letter stated that the Staff would commence delisting proceedings against the Company. The Company has been provided wit”

PALISADE BIO, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“October 19, 2023, Palisade Bio, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that for 30 consecutive trading days preceding the date of the Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Notice has no effect on the listing of the Company’s common stock at this time, and the Company’s common stock continues to trade on The Nasdaq C”

Sintx Technologies, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“October 20, 2023, SINTX Technologies, Inc. (“SINTX” or “the Company”) received a notice from Nasdaq Listing Qualifications department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the bid price of the Company’s common stock for the last 30 consecutive trading days had closed below the minimum $1.00 per share required for continued listing under Listing Rule 5550(a)(2). The Nasdaq notification letter does not result in the immediate delisting of the Company’s common stock, and the stock will continue to trade uninterrupted on the The Nasdaq Capital Market under the symbol”

SPI Energy Co., Ltd. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“October 19, 2023, SPI Energy Co., Ltd., a Cayman Islands company (the “Company”) received a notice in the form of a letter (“Deficiency Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) because the bid price for the Company’s ordinary shares had closed below $1.00 per share for the previous 30 consecutive business days (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been given 180 calenda”

COMSovereign Holding Corp. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“October 16, 2023, COMSovereign Holding Corp. (the “Company”) received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Staff had determined to delist the Company’s securities unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Staff’s determination was based upon the Company’s continued non-compliance with the filing requirement set forth in Nasdaq Listing Rule 5250(c)(1) because the Company has not filed its Form 10-K for the year ended December 31, 2022, and the Forms 10-Q for”

BIOCEPT INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 17, 2023, Staff also notified the Company that it failed to maintain a minimum of $2,500,000 in stockholders’ equity required for continued listing pursuant to Listing Rule 5550(b)(1), which deficiency serves as an additional and separate basis for delisting. The Staff letter indicates that the trading of the Company’s common stock and warrants will be suspended at the opening of business on October 25, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. The Company does not i”

BIOCEPT INC received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“October 16, 2023, the Company received a letter (“Delisting Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff had determined that the Company’s securities will be delisted from Nasdaq pursuant to Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, in connection with the filing of a voluntary case under Chapter 7 of Title 11 of the United States Bankruptcy Code, 11 U.S.C. §§ 101 et seq. (the “Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) on October 13, 202”

DMK PHARMACEUTICALS Corp received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

“October 11, 2023, the Company received notice from the Staff that, due to the Company’s failure to regain compliance with the minimum $35 million market value of listed securities (“MVLS”) requirement set forth in Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”) during the 180-day grace period previously granted to the Company that expired on October 9, 2023, the Company’s common stock was subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”). In response, the Company timely requested a hearing before the Panel, which request stayed a”

DMK PHARMACEUTICALS Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“October 18, 2023, the Company received a superseding notice from the Staff (the “Subsequent Notice”), indicating that the Prior Notice was issued in error. The Subsequent Notice indicated that because the Company was subject to a one-year Mandatory Panel Monitor as a result of a prior hearing before the Panel, the Company was not eligible for the automatic 180-day compliance grace period provided by Listing Rule 5810(c)(3)(A) and that the Company’s non-compliance with the Bid Price Rule serves as an additional basis for delisting from Nasdaq. At the hearing, the Company will address its plan t”

CURO Group Holdings Corp. received a nyse deficiency notice notice regarding market value (rules 802.01B).

“equity was less than $50 million. As set forth in the Notice, as of October 16, 2023, the 30 trading-day average global market capitalization of the Company was approximately $44.7 million and the Company’s last reported stockholders’ deficit as of June 30, 2023 was $268.4 million. In accordance with NYSE listing requirements, the Company has notified the NYSE that”

Liberty TripAdvisor Holdings, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5460(b), 5450(b)).

“October 19, 2023, Liberty TripAdvisor received written notice from Nasdaq notifying Liberty TripAdvisor that trading of LTRPA and Liberty TripAdvisor’s Series B common stock, par value $0.01 per share (“LTRPB”), will be suspended at the open of business on October 30, 2023 due to LTRPA’s failure to regain compliance with the Minimum Bid Price Requirement by October 18, 2023 and LTRPB’s failure to satisfy the continued listing requirements under Nasdaq Listing Rule 5460(b) necessary to maintain a separate “primary equity security” listing independent of LTRPA, specifically the requirements set”

Liberty TripAdvisor Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“April 21, 2023, Liberty TripAdvisor Holdings, Inc. (“Liberty TripAdvisor”) received written notice (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) notifying Liberty TripAdvisor that, because the closing bid price for Liberty TripAdvisor’s Series A common stock, par value $0.01 per share (“LTRPA”), had fallen below $1.00 per share for 30 consecutive business days, Liberty TripAdvisor no longer complied with the minimum bid price requirement for continued listing of LTRPA on the Nasdaq Global Select Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bi”

Village Farms International, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“October 18, 2023, the Company received notification from Nasdaq that Nasdaq has approved the Company’s request for a 180-calendar day extension (the “ Extension ”) to regain compliance with the Minimum Bid Requirement. The Extension follows the expiration on October 17, 2023 of the initial 180-calendar day period to regain compliance with the Minimum Bid Requirement. As a result of the Extension, the Company now has until April 15, 2024 (the “ New Compliance Period ”) to regain compliance with the Minimum Bid Requirement. The Extension has no immediate effect on the listing of the Common Share”

Pluri Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“April 19, 2023, Pluri Inc., a Nevada Corporation (the “Company”), received a written notification (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that for 30 consecutive trading days preceding the date of the Notice, the bid price of the Company’s common shares, par value $0.00001 per share (the “Common Shares”), had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). Pursuant t”

Adamas One Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“October 12, 2023, Adamas One Corp . (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, $0.001 par value per share (the “Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Req”

Aetherium Acquisition Corp received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“August 23, 2023, the Company received another late filer notification from the Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of an additional delinquency and non-compliance with the Rule resulting from the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023. As a result of this additional delinquency of not timely filing the Form 10-Q for the quarter ended June 30, 2023, the Company was requested to submit to Nasdaq by September 7, 2023 an update to the Company’s original plan to regain compl”

Royalty Management Holding Corp received a nasdaq delisting notice notice regarding market value.

“October 13, 2023, American Acquisition Opportunity Inc. (the “Company”) filed a Current Report on Form 8-K (the “Form 8-K”) reporting that as it had not timely filed for an appeal of the delisting notification it had received a letter from the Staff stating that as the Company had not regained compliance with the MVLS Rule, its securities would be delisted effective as of the opening of the market on October 16, 2023. Nasdaq subsequently determined that due to extenuating circumstances, it would permit the Company to appeal and trading resumed on October 18, 2023 pending the hearing which has”

ShiftPixy, Inc. received a nasdaq noncompliance notice notice regarding other (rules 5635(d)).

“October 18, 2023, the Company received a letter from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), which notified the Company that, in connection with the Company’s private placement that closed on October 10, 2023, the Company failed to comply with Nasdaq’s shareholder approval requirements set forth in Listing Rule 5635(d)1 (the “Rule”), which requires prior shareholder approval for transactions, other than public offerings, involving the issuance of 20% or more of the pre-transaction shares outstanding at less than the Minimum Pr”

ATHERSYS, INC / NEW received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

“October 16, 2023, the Company received a delisting determination letter from Nasdaq advising the Company that the Panel had determined that the Company was unable to demonstrate compliance with the MVLS Requirement. As a result trading of the Company’s common stock will be suspended at the opening of business on October 18, 2023, and a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission, removing the Company’s securities from listing and registration on Nasdaq. The Company may, but currently does not intend to, request an appeal of the Panel's determination with Nasdaq.”

Lexaria Bioscience Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“October 17, 2023, Lexaria Bioscience Corp. (the “Company”) received a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Bid Price Deficiency Notice has no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade on the Nasdaq Capital Market”

LIFECORE BIOMEDICAL, INC. DE received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“n filing its Annual Report on Form 10-K for the period ended May 28, 2023 (the “Form 10-K” and, together with the Form 10-Q, the “Filings”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The notification letter has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Global Select Market. In accordance with the instructions contained in the Notice, the Company submitted a plan to regain compliance with the Listing”